Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Proposes Antihypertensive Class Indication For Reducing CV Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Adding an indication for reducing cardiovascular adverse event risk is one option FDA will have its Cardiovascular & Renal Drugs Advisory Committee consider for antihypertensive class labeling June 15. Other class labeling options offered in FDA briefing document would amend the clinical trials section.

You may also be interested in...



Pfizer To Present ALLHAT Analysis At Advisory Committee On Antihypertensive Labeling

The company will present a non-inferiority analysis suggesting Norvasc (amlodipine) is similar to the diuretic chlorthalidone in preventing hypertension outcomes during a June 15 meeting of FDA's Cardiovascular & Renal Drugs Advisory Committee, the agency says.

Pfizer To Present ALLHAT Analysis At Advisory Committee On Antihypertensive Labeling

The company will present a non-inferiority analysis suggesting Norvasc (amlodipine) is similar to the diuretic chlorthalidone in preventing hypertension outcomes during a June 15 meeting of FDA's Cardiovascular & Renal Drugs Advisory Committee, the agency says.

NitroMed BiDil Heart Failure Indication For African Americans To Be Reviewed By Cmte.

FDA's Cardiovascular & Renal Drugs Advisory Committee will meet June 16 to consider the resubmitted BiDil NDA. Drug could be first approval specifically for African Americans. Committee will also meet June 15 to discuss antihypertensive class labeling.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel